Danni Folkard will discuss the following topics in conjunction with customer case studies:​

• Obtaining genomic and epigenomic data from a single dataset to directly analyse native DNA to uncover genomic variants alongside methylation status in a single nanopore sequencing run.​

• Going beyond gene-level analysis for transcriptomic sequencing to gain isoform-level expression information with full-length transcript sequencing and identify fusions with ease using native RNA or cDNA sequencing.​

• Harnessing single cell transcriptomic insights by analysing full-length transcripts from single cells to reveal biology hidden by short reads to shed light on cellular heterogeneity with a comprehensive view of isoform diversity, alternative splicing and expressed variants.​

Resolving the mechanisms underpinning human diseases is vital to understand disease phenotypes, identify novel biomarkers, and enable drug discovery. Multiomic approaches — spanning genomics, epigenetics, bulk and single-cell transcriptomics, and proteomics — are crucial to this, providing data to help unravel complex pathways. In disease research, tissue samples are invaluable and scarce resources; maximising the information obtained from these samples is essential. However, legacy multiomic methods require the use of multiple platforms and often involve complex workflows, lengthy turnaround times, and considerable costs. Even when combining data from multiple traditional technologies, valuable information is missed from precious research samples, leaving important biological mechanisms unresolved.​

In this talk, Danni Folkard, Oxford Nanopore Technologies, will showcase how multiomic Oxford Nanopore sequencing can accelerate your research, from rare disease to oncology — all on a single platform with flexible and fast nanopore sequencing workflows to provide informative results in meaningful turnaround times.